focus -WSS

focus

author：knowledge 2025-09-30 15:22:45 - browse：8

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： The kidney, in all its complexity, is captured in a new atlas

hotspot

WSS

Couple fighting to bring baby home from Mexico are finally reunited

Feng Zhang CRISPR delivery startup lays off quarter of staff

The biotech scorecard for Q1: 17 stock

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Celebrate National Dole Whip Day for 3 days this week at Disney

The kidney, in all its complexity, is captured in a new atlas

focus

focus

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Feng Zhang CRISPR delivery startup lays off quarter of staff

In age of alternative facts, a scholarly course on calling out crap

Feng Zhang, Grail founder join forces on new gene editing startup

Tori Bowie and the unacceptable rates of Black maternal death

A single drug, study failures leave Anavex with nothing but cash

BioMarin wins approval for gene therapy to treat hemophilia A

Morgan Health, with ambitious aims, wants you to know it’s still here

Walensky prepares to leave CDC — and Congress — behind

3 trends to watch in health tech's hiring outlook for 2024

knowledge

Videos point to link between seizures and unexplained toddler deaths

GSK Flovent asthma inhalers replaced by authorized generics

How dance can help health care workers heal from trauma

New weight loss drugs work. But how can they best be used?

The FDA must approve intranasal treatments for anaphylaxis

GSK Flovent asthma inhalers replaced by authorized generics

focus

hotspot

hotspot

explore